N. Dickgreber (Sarstedt, Germany), E. Jassem (Gdansk, Poland)
Circulating cell free RNA level and clinical response to the chemotherapy in patients with thoracic malignancy
S. J. Um, S. K. Lee, C. Son, K. E. Lee, M. S. Rho, I. S. Choi, J. Huh (Busan, Republic Of Korea)
|  |
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy
W. Naumnik, E. Chyczewska, M. Ossolinska (Bialystok, Poland)
|  |
Leptin: in the diagnose of lung cancer
Z. Sonmez, S. Duru, Y. Saygideger, O. Sever, B. Onal, O. Ergul, G. Dikmen, S. Ardic (Ankara, Turkey)
| |
EGFR – a useful biomarker?
A. Antunes, J. Gomes, C. Lima, P. Brinca, J. C. Machado, B. Parente (Vila Nova Gaia, Porto, Portugal; Stckholm, Sweden)
| |
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC)
R. Zalacain, J. Algorta, N. Marina, A. Gomez, M. Uribarri, B. Calvo, S. Carrera, S. Pedrero, G. Lopez-Vivanco (Baracaldo, Zamudio, Spain)
| |
Are there potential characteristical markers in bronquial fluid for diagnosis of small cell lung cancer (SCLC)?
N. Marina, J. Algorta, G. Lopez-Vivanco, S. Carrera, M. Uribarri, S. Pedrero, U. Aresti, A. Gomez, R. Zalacain (Baracaldo, Zamudio, Spain)
| |
Clinical significance of serum adipokines levels in lung cancer
T. Kerenidi, A. Tsaroucha, M. Lada, P. Georgoulias, P. Mystridou, K. Gourgoulianis, K. Kostikas (Larissa, Greece)
| |
Systemic inflammation: a link between chronic obstructive pulmonary disease and lung cancer?
J. A. Torrecilla, J. Sauleda, B. Cosío, E. Monsó, A. Noguera, A. Rosell, A. Iglesias, L. Millares, N. Rodríguez, A. Agustí (Palma de Mallorca, Madrid, Badalona, El Prat de Llobregat, Bunyola, Barcelona, Spain)
| |
PAK interacting exchange factor (BPIX-a) overexpression in human lung cancer
S. S. Sheen, H. L. Lim, Y. S. Kim, K. S. Lee, W. Y. Chung, J. H. Park, K. J. Park, S. C. Hwang (Suwon, Republic Of Korea)
| |
Systemic inflamation and bronchial dysplasia in risk lung cancer subjects
N. Rodriguez, F. Andreo, J. Sanz, E. Monsó, L. Setó, J. Sauleda, F. De Borja, A. Noguera, A. Rosell (Vilafranca del Penedès, Badalona, Palma de Mallorca, Spain)
| |
Increase of activated/memory and decrease of naive T cells with unchanged frequency of regulatory T cells in blood of lung cancer patients
G. Galffy, D. Bartusek, A. Cseh, Z. Komlósi, G. Losonczy (Budapest, Hungary)
| |
Activation of NRF2 is responsible for the overexpression of peroxiredoxin and sulphiredoxin in human lung cancer
S. C. Hwang, H. L. Lim, Y. S. Kim, K. S. Lee, W. Y. Chung, J. H. Park, S. S. Sheen, K. J. Park (Suwon, Republic Of Korea)
| |
Probing the carcinogenic potential of carbon nanotubes
M. Clift, P. Wick, P. Gehr, R. Schins, B. Rothen-Rutishauser (Bern, St. Gallen, Switzerland; Duesseldorf, Germany)
| |
EGFR and hTERT expression in high risk COPD patients – clinical application
R. Cherneva, O. Georgiev, D. Petrova, D. Petrov, D. Toncheva (Sofia, Bulgaria)
| |
Radiation burden of the up clearing deeply deposited radon progenies in the central airways
I. Horvàth, G. Kudela, I. Balashazy, B. G. Madas (Budakeszi, Remeteszolos, Budapest, Hungary)
| |
Clinical significance of serum survivin, MGB-1 and Pref-1 levels during chemotherapy of lung cancer
W. Naumnik, E. Chyczewska (Bialystok, Poland)
| |
Karyometric analysis of squamous metaplasia, dysplasia and squamous cell carcinoma of the lung
Z. Mijovic, D. Mihailovic, M. Kostov (Nis, Republic Of Serbia)
| |
Lactate dehydrogenase as a biomarker in brochoalveolar lavage of patients with lung cancer
M. Saba, A. Emad (shiraz, Islamic Republic Of Iran)
| |
Cytology in differential diagnosis of histological types of NSCLC
J. Domagala-Kulawik, R. Krenke, R. Chazan (Warsaw, Poland)
| |